Abstract
Fifteen patients with advanced head and neck cancer not curable with radiation or surgery were entered into a phase II study of 10-EdAM. None of the patients had received prior chemotherapy. 10-EdAM was administered intravenously at a dose of 80 mg/m2 each week. Four patients were not eligible for evaluation. Two died before completing four cycles of chemotherapy, one refused further treatment and one developed hepatic toxicity resulting in withdrawal. Of the remaining patients, three had a partial response. The major toxicities were leukopenia and mucositis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sirotnak FM, Degraw JI, Schmid FA: New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemotherapy Pharmacol 12:26–30, 1984
Kris MG, Kinahan JJ, Gralla RJ: Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deaza-aminopterin in adult patients with advanced cancer. Cancer Res 48:5573–5579, 1988
Shum KY, Kris MG, Gralla RJ: Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non small cell lung cancer. J Clin Oncol 6:446–450, 1988
Brunner K, Crowther D, Eckhardt S, Olive D, Tanneberger S, Veronesi A, Whitehouse J, Wittes R, Monfardin S (Eds): Manual of Adult and Paediatric Medical Oncology. Internation Unit Against Cancer (UICC), Springer Verlag, Berlin, 11–38, 1987
Schornagel JH, Cappalaere P, Cognetti F: A randomized phase II trial of 10-ethyl-10-deaza-aminopterin (10-EdAM) in patients with advanced squamous cell cancer of the head and neck. Proceedings of the sixth NCI-EORTC symposium on new drugs in cancer therapy. Abstract 462 March, 1989
Robert F: Trimetrexate as a single agent in patients with advanced head and neck cancer. Semin Oncol 1988 April, 15(2 Suppl 2):22–6
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Green, M.D., Sherman, P. & Zalcberg, J. Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy. Invest New Drugs 10, 31–34 (1992). https://doi.org/10.1007/BF01275477
Issue Date:
DOI: https://doi.org/10.1007/BF01275477